Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1α and HIF-2α, or expression vectors thereof.
1. A method of treating a retinal disease associated with angiogenesis in a subject by inhibiting VEGF, the method comprising topically administering an effective amount of siRNA for HIF-1α and an effective amount of siRNA for HIF-2α to the eye of the subject, thereby inhibiting VEGF and treating the retinal disease associated with angiogenesis in the subject.
2. The method according to claim 1 , wherein the aforementioned siRNA for HIF-1α consists of a sense strand comprising a sequence of 17-25 continuous bases of mRNA corresponding to the base sequence of SEQ ID NO: 1 and an antisense strand comprising a sequence complementary thereto, and the aforementioned siRNA for HIF-2α consists of a sense strand comprising a sequence of 17-25 continuous bases of mRNA corresponding to the base sequence of SEQ ID NO: 3 and an antisense strand comprising a sequence complementary thereto, and wherein the sense strand and antisense strand are 17-25 bases in length.
3. The method according to claim 1 , wherein the aforementioned siRNA for HIF-1α is the following (a) or (b), and siRNA for HIF-2α is the following (c) or (d):
(a) a double strand RNA composed of a sense strand comprising a base sequence described in any of SEQ ID NOs: 17-20 and 31, and an antisense strand comprising a sequence complementary thereto, which optionally has an overhang at the terminal of the sense strand and/or the antisense strand, and has HIF-1α expression-inhibitory activity;
(b) a double strand RNA composed of a sense strand comprising a base sequence wherein one to several bases have been added to and/or deleted from the 5′ terminal and/or 3′ terminal of the base sequence described in any of SEQ ID NOs: 17-20 and 31, and an antisense strand comprising a sequence complementary thereto, which optionally has an overhang at the terminal of the sense strand and/or the antisense strand, and has HIF-1α expression-inhibitory activity;
(c) a double strand RNA composed of a sense strand comprising the base sequence described in any of SEQ ID NO: 21, 22 and 35, and an antisense strand comprising a sequence complementary thereto, which optionally has an overhang at the terminal of the sense strand and/or the antisense strand, and has HIF-2α expression-inhibitory activity;
(d) a double strand RNA composed of a sense strand comprising a base sequence wherein one to several bases have been added to and/or deleted from the 5′ terminal and/or 3′ terminal of the base sequence described in any of SEQ ID NOs: 21, 22 and 35, and an antisense strand comprising a sequence complementary thereto, which optionally has an overhang at the terminal of the sense strand and/or the antisense strand, and has HIF-2α expression-inhibitory activity.
4. The method according to claim 1 , wherein the aforementioned siRNA for HIF-1α is any of the following (1-1)-(1-5), and siRNA for HIF-2α is any of the following (2-1)-(2-3):
(1-1) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 5, and an antisense strand consisting of the base sequence described in SEQ ID NO: 11;
(1-2) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 6, and an antisense strand consisting of the base sequence described in SEQ ID NO: 12;
(1-3) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 7, and an antisense strand consisting of the base sequence described in SEQ ID NO: 13;
(1-4) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 8, and an antisense strand consisting of the base sequence described in SEQ ID NO: 14;
(1-5) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 29, and an antisense strand consisting of the base sequence described in SEQ ID NO: 30;
(2-1) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 9, and an antisense strand consisting of the base sequence described in SEQ ID NO: 15;
(2-2) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 10, and an antisense strand consisting of the base sequence described in SEQ ID NO: 16;
(2-3) a double strand RNA composed of a sense strand consisting of the base sequence described in SEQ ID NO: 33, and an antisense strand consisting of the base sequence described in SEQ ID NO: 34.
5. The method according to claim 1 , wherein the retinal disease associated with angiogenesis is age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, retinal artery obstruction, diabetic macular edema or glaucoma.
6. The method according to claim 5 , wherein the retinal disease associated with angiogenesis is age-related macular degeneration or diabetic retinopathy.